CINCINNATI, OH / ACCESSWIRE / August 17, 2018 / Callitas Health Inc. (CSE: LILY, OTCQB: MPHMF, FWB: T3F2), (the "Company" or "Callitas") today announced that it has signed a consulting agreement with BFS Innovations and Pure Leaf Group to launch Callitas' patent-pending cannabis delivery technology and proprietary business model globally.
"BFS Innovations and Pure Leaf Group are excited to be partnering with Callitas as it brings its proprietary actives delivery system and tightly controllable dosing technology to this rapidly growing market," says Scott Allen, president of Pure Leaf Group, "CannaStrip's proprietary actives delivery system and tightly controllable sublingual dosing technology are key differentiators for companies who are seeking a competitive edge in the rapidly emerging cannabis marketplace."
"This partnership allows Callitas to expand its reach and engage more groups locally and internationally," said James Thompson, President and CEO. "Our CannaStrip technology is amazing, and as we continue to expand our IP portfolio of cannabis tech, Callitas will be able to leverage BFS Innovations and Pure Leaf Group's experience to grow sales."
Callitas, which focuses on developing innovative technologies for both OTC and drug markets, is focused on bringing pharmaceutical best practices to the cannabis space through controlled dosing, improved bioavailability and advanced manufacturing techniques. The Company also develops ground-breaking technologies for weight management and female health and wellness.
"Our proprietary business model for manufacturing and distribution is novel and efficient. By partnering with BFS Innovations and Pure Leaf Group, we are accelerating our speed-to-market on a state-by-state level, which is very exciting." said Joshua Maurice, Director of Sales and Marketing.
About BFS Innovations, Inc:
BFS Innovations helps clients to solve diverse new product development challenges, including identifying unique solutions that competitors wouldn't think to consider.
About Pure Leaf Group, LLC:
Pure Leaf Group was founded to meet the needs of the rapidly evolving and highly-regulated cannabis industry. Our dynamic team provides complete consulting and product development solutions for companies entering or currently operating in the growing cannabis and CBD market. Pure Leaf Group has developed operating partnerships with key partners to help our clients build the necessary infrastructure to bring safe, consistent, and innovative products to medical patients and recreational consumers.
About Callitas Health:
Formed in early 2015, Callitas Health Inc. is an integrated clinical-stage pharmaceutical development and OTC consumer goods marketing company, focused on developing innovative technologies for weight management, female sexual health and wellness, cannabis delivery technologies and other proprietary drugs. In addition to its recent acquisitions of C-103, a reformulation of Orlistat, Extrinsa and assets from 40J's LLC, the Company successfully launched ToConceive in North America as a clinically proven option for couples struggling with the inability to conceive (www.toconceive.com), and is in the research and development and business development process for its other OTC products, CannaMint strips and orphan drug technologies. For more information visit www.callitas.com.
Contacts:
Callitas Health:
James Thompson, CEO, or
Callitas Investor Relations
Phone: +1 (859) 868-3131
TraDigitalIR:
Investor Relations - Kevin McGrath, Managing Director
Phone: +1 (646) 418-7002
Notice regarding Forward Looking Statements:
This news release contains forward-looking statements. The use of any of the words "anticipate,'' " continue,'' "estimate,'' " expect,'' "may,'' "will,'' "project,'' " should,'' "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval and the commercialization of the rights to the Company's biomedical & drug technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Company's filings to the CSE at www.thecse.com. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.
Notice regarding investigational devices:
CannaMint Strips, C-103 and Extrinsa are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body. Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
Statements in this press release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve a high degree of risk and uncertainty, are predictions only and actual events or results may differ materially from those projected in such forward-looking statements.
SOURCE: Callitas Health, Inc.
